BreakBio
BreakBio Corp is pioneering personalized cancer treatment through its AI/ML platform, which tailors therapies for solid cancers at any stage. Founded in 2019, the company focuses on developing a patent-pending personalized cancer vaccine that targets multiple proteins unique to each patient's cancer cells. This innovative approach aims to create effective treatments across all cancer types, leveraging mass spectrometry and AI to manufacture customized drugs. BreakBio's mission is to achieve FDA breakthrough therapy designation and provide hope for patients with high mutation counts and those with low mutation counts in their cancer.
BreakBio
BreakBio Corp is pioneering personalized cancer treatment through its AI/ML platform, which tailors therapies for solid cancers at any stage. Founded in 2019, the company focuses on developing a patent-pending personalized cancer vaccine that targets multiple proteins unique to each patient's cancer cells. This innovative approach aims to create effective treatments across all cancer types, leveraging mass spectrometry and AI to manufacture customized drugs. BreakBio's mission is to achieve FDA breakthrough therapy designation and provide hope for patients with high mutation counts and those with low mutation counts in their cancer.